The National Institutes of Health has awarded a Washington University in St. Louis faculty member in the School of Engineering & Applied Science a total of $1.3 million to study new imaging techniques designed to better fight ...
Mar 30, 2017
0
0
Mutations in the BRCA1 gene are one of the most common risk factors for breast and ovarian cancers. Although tumors that harbor BRCA1 mutations initially respond well to cancer treatments, many tumors eventually become less ...
Jul 25, 2016
0
82
A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during ...
Jun 15, 2016
0
24
University of Arizona researcher Jennifer Barton is leading a two-year, $1 million project funded by the National Cancer Institute to identify imaging biomarkers of ovarian cancer, the most deadly gynecological cancer in ...
May 31, 2016
0
11
A team from the Catalan Institute of Oncology and Bellvitge Biomedical Research Institute (ICO-IDIBELL) has developed a new animal models that reproduce faithfully the evolution and malignancy of different human tumors.
Jan 22, 2015
0
2
Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...
Aug 15, 2013
0
0
Interferons have antitumor activity and have been used to treat a variety of malignancies, including colorectal and ovarian cancers. However, their effectiveness varies. A clearer understanding of the role of interferon in ...
Apr 16, 2013
0
0
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...
Apr 15, 2013
0
1
Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian ...
Oct 9, 2012
0
0
Dr. Anglea Wandinger-Ness and Dr. Laurie Hudson were awarded a Provocative Questions grant to investigate the use of R-ketorolac against ovarian cancer. Ketorolac is an NSAID that the FDA approved for human use in 1991. They ...
Sep 27, 2012
0
0
